[Effect of Ganoderma lucidum polysaccharides on intestinal mucosal immune system in H22 liver cancer bearing mice].
OBJECTIVE
To observe the mucosal immune mechanism of anti-tumor action of Ganoderma lucidum polysaccharides (GLP).


METHODS
The concentration of H22 cells in suspension were adjusted to 1 x 10(9)/ L, and 0.2 mL of the cell suspension was injected subcutaneously in the right oxter of Kunming mice. Then the H22 bearing mice were randomly divided into 4 groups: the GLP group, the Cytoxan (CTX) group, the CTX + GLP group and the untreated model group, 8 mice in each group. Besides, a blank control group was set up. Starting from the 2nd day of modeling, GLP, at the dose of 1.02 g/kg was given to GLP group and GLP + CTX group by gastrogavage once a day for 12 successive days; CTX at the dose of 100 mg/kg was administered via peritoneal injection to the CTX group and the GLP + CTX group on the 1st day and the 6th day of the experimental course; but to the model group and the blank group, only equal volume of distilled water was given. All mice were sacrificed on the 14th day, the ileum at 1 cm upper to cecum was taken, through 4% paraform fixation and paraffin section, it was used for immunohistochemical detecting expressions of immunoglobulin A (IgA), tumor necrosis factor-alpha (TNF-alpha), interleukin-2 (IL-2) and interleukin-10 (IL-10) in ileum. Besides, the lymphocyte subsets in the intraepithelial lymphocyte (IEL), lamina propria lymphocytes (LPL), and Peyer's patch lymphocytes (PPL) were analyzed by immune fluorescence technique and flow cytometry.


RESULTS
Compared with the blank control group, the phenotype of lymphocytes and the expression of cytokines in ileum in the model group changed significantly; and the phenotype was variant in different regions. Compared with the model group, both indexes were adjusted in the GLP, CTX and GLP + CTX group to different degrees.


CONCLUSIONS
The adjustment of GLP on intestinal mucosal immune is probably another path for its anti-tumor action.
Zhou
Gui-Qin
GQ
Department of Integrative Medicine, Beijing Ditan Hospital, Beijing.
Zhao
Hong-Yan
HY
Lu
Cheng
C
D000818:Animals; D000972:Antineoplastic Agents, Phytogenic / Q000494:pharmacology*; D004365:Drugs, Chinese Herbal / Q000494:pharmacology; D007070:Immunoglobulin A / Q000378:metabolism; D007376:Interleukin-2 / Q000378:metabolism; D007413:Intestinal Mucosa / Q000276:immunology*; D008114:Liver Neoplasms, Experimental / Q000276:immunology*; D008297:Male; D051379:Mice; D008815:Mice, Inbred Strains; D011134:Polysaccharides / Q000302:isolation & purification / Q000494:pharmacology*; D011897:Random Allocation; D020940:Reishi / Q000737:chemistry*; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism
D000972:Antineoplastic Agents, Phytogenic; D004365:Drugs, Chinese Herbal; D007070:Immunoglobulin A; D007376:Interleukin-2; D011134:Polysaccharides; D014409:Tumor Necrosis Factor-alpha